The likelihood for development of cutaneous melanoma may be greater for individuals with iris pigmented lesions, according to a study.
AJCC8 tumor classification demonstrated significantly superior homogeneity and monotonicity to AJCC7 tumor classification.
Investigators sought to evaluate whether age is associated with risk for immune-related adverse events among patients with metastatic melanoma treated with immunotherapy.
Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.
A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.
The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.
Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.
Transplant recipients developed squamous cell carcinomas that did not appear to behave more aggressively than those that developed in the immunocompetent group.
A reduced risk of squamous cell carcinoma, but not basal cell carcinoma, was observed for one year in at-risk individuals treated with fluorouracil.
Individuals with a history of atopic dermatitis have a higher risk of squamous cell carcinoma development, research indicates.
An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.
Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.
Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.
[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.
[OncoTargets and Therapy] A review of the role of chemotherapy in the treatment of Merkel cell carcinoma in view of the recent FDA approval of the PD-L1 antibody avelumab and limited and controversial data on the efficacy of chemotherapy in this disease.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
High occupational UV exposure tied to two-fold increase in skin cancer risk, but prevention strategies in work environments are often underutilized.
Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care ProvidersAugust 11, 2017
Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.
Researchers found that an association between alcohol consumption and nonmelanoma skin cancers may be dose-dependent. This risk includes basal cell carcinoma and cutaneous squamous cell carcinoma.
The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.
Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.
A common beta blocker, carvedilol, is found to have preventive properties against the sun-induced cell damage that leads to skin cancer.
Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.
Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.
Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.
Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.
Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.
Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.
Skin cancers from ultraviolet light in tanning devices totaled $343.1 million in 2015 alone, researchers say.
Sign Up for Free e-newsletters
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Medical Terms in Patient Education: Using the Confusing to Explain the Complicated
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Ciprofloxacin Plus Doxycycline Reduces Infection Rate in Multiple Myeloma Post-ASCT
- Prognostic Significance of Epidermal Growth Factor Receptor Expression in Glioma Patients
- Fathers Can Pass Inherited Ovarian Cancer Risk to Daughters
- Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer
- Nabilone Improves Cancer-Associated Anorexia in Lung Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|